Bexirestrant

A selective estrogen receptor degrader

Bexirestrant
[[File: Chemical structure of Bexirestrant |frameless|220px|alt=|]]
INN
Drug class	Selective estrogen receptor degrader
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Bexirestrant is a selective estrogen receptor degrader (SERD) that is being investigated for the treatment of hormone receptor-positive breast cancer. It is designed to bind to the estrogen receptor and promote its degradation, thereby inhibiting the growth of estrogen-dependent tumors.

Mechanism of Action

Bexirestrant functions by binding to the estrogen receptor (ER) and inducing a conformational change that targets the receptor for degradation. This process reduces the number of functional estrogen receptors available in the cell, thereby diminishing the estrogen signaling that can promote the growth of certain types of breast cancer. Unlike selective estrogen receptor modulators (SERMs), which block the receptor's activity, SERDs like bexirestrant lead to the receptor's destruction.

Clinical Development

Bexirestrant is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hormone receptor-positive breast cancer. These trials aim to determine the optimal dosing regimen and to compare its effectiveness with existing therapies such as fulvestrant, another SERD.

Pharmacokinetics

The pharmacokinetic profile of bexirestrant includes its absorption, distribution, metabolism, and excretion. It is administered orally, and studies are ongoing to understand its bioavailability and half-life. The drug is metabolized in the liver, and its metabolites are excreted primarily through the feces.

Potential Benefits

Bexirestrant offers potential benefits over existing therapies by providing a more complete degradation of the estrogen receptor, which may lead to improved outcomes in patients with resistant forms of breast cancer. Its oral administration also offers a more convenient alternative to injectable therapies.

Side Effects

As with many cancer therapies, bexirestrant may have side effects. Commonly observed adverse effects in clinical trials include fatigue, nausea, and hot flashes. Ongoing studies are monitoring for any long-term effects and the overall safety profile of the drug.

Related Pages

• Breast cancer
• Estrogen receptor
• Selective estrogen receptor degrader
• Fulvestrant